How big is IGM Biosciences, Inc.?

As of Jun 18, IGM Biosciences, Inc. has a market capitalization of 71.54 million and reported net sales of 2.68 million with a net profit of -198.87 million over the latest four quarters. Shareholder's funds are at 48.17 million, and total assets amount to 265.71 million as of Dec 24.

As of Jun 18, IGM Biosciences, Inc. has a market capitalization of 71.54 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 2.68 million, while the sum of Net Profit for the same period is -198.87 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 48.17 million and Total Assets at 265.71 million.

What does IGM Biosciences, Inc. do?

IGM Biosciences, Inc. is a biotechnology company focused on developing engineered IgM antibodies for cancer treatment. As of March 2025, it has a market cap of $71.54 million, with net sales of $0 and a net loss of $53 million.

Overview: <BR>IGM Biosciences, Inc. is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of cancer patients, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -53 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 71.54 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -145.10 <BR>Return on Equity: -16,082.30% <BR>Price to Book: 71.54<BR><BR>Contact Details: <BR>Address: 325 E Middlefield Rd, MOUNTAIN VIEW CA: 94043-4003 <BR>Tel: ['1 650 9657873', '1 212 6001902'] <BR>Fax: 1 302 6555049 <BR>Website: http://igmbio.com/

Should I buy, sell or hold IGM Biosciences, Inc.?

Who are in the management team of IGM Biosciences, Inc.?

As of March 2022, the management team of IGM Biosciences, Inc. includes Independent Chairman Mr. Michael Loberg, President and CEO Mr. Fred Schwarzer, and Independent Directors Dr. M. Kathleen Behrens, Dr. Julie Hambleton, Mr. Michael Lee, Dr. Kelvin Neu, and Dr. William Strohl. They oversee the company's strategic direction and operations.

As of March 2022, the management team of IGM Biosciences, Inc. includes the following individuals:<BR><BR>- Mr. Michael Loberg, who serves as the Independent Chairman of the Board.<BR>- Mr. Fred Schwarzer, who is the President, Chief Executive Officer, and Director.<BR>- Dr. M. Kathleen Behrens, who is an Independent Director.<BR>- Dr. Julie Hambleton, who is also an Independent Director.<BR>- Mr. Michael Lee, serving as an Independent Director.<BR>- Dr. Kelvin Neu, who is an Independent Director.<BR>- Dr. William Strohl, who is an Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Is IGM Biosciences, Inc. overvalued or undervalued?

As of March 30, 2023, IGM Biosciences, Inc. is considered risky and overvalued, with a Price to Book Value of 79.35 and significant underperformance of -79.21% year-to-date compared to the S&P 500's gain of 12.22%.

As of 30 March 2023, the valuation grade for IGM Biosciences, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company is overvalued based on its current metrics, particularly highlighted by a Price to Book Value of 79.35, an EV to EBIT of 0.38, and an EV to EBITDA of 0.41. In comparison to peers, Lexicon Pharmaceuticals, Inc. has a more favorable EV to EBITDA of -2.8670, while Vanda Pharmaceuticals, Inc. shows an EV to EBITDA of 0.5601, suggesting that IGM may be lagging behind its competitors.<BR><BR>The stock has significantly underperformed against the S&P 500, with a year-to-date return of -79.21% compared to the index's gain of 12.22%. This stark contrast reinforces the notion that IGM Biosciences, Inc. is not only facing valuation challenges but is also struggling to deliver returns in the current market environment.

Is IGM Biosciences, Inc. technically bullish or bearish?

As of July 1, 2025, IGM Biosciences, Inc. is in a mildly bearish trend, with mixed technical indicators and significant underperformance, showing a year-to-date return of -79.21% compared to the S&P 500's 12.22%.

As of 1 July 2025, the technical trend for IGM Biosciences, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by a combination of indicators. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly. The moving averages are mildly bearish on the daily timeframe, and both the KST and OBV indicate a mildly bearish stance on the weekly. Dow Theory remains bearish on both weekly and monthly timeframes.<BR><BR>In terms of performance, IGM Biosciences has significantly underperformed against the S&P 500, with a year-to-date return of -79.21% compared to the S&P 500's 12.22%, and a one-year return of -86.3% versus the S&P 500's 17.14%.